Affiliation:
1. Department of Haematology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel
2. Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel
Abstract
AbstractObjectivesTo evaluate whether low‐dose belantamab mafodotin (B‐MAF) dosing results in lower toxicity and better overall outcome.MethodsWe retrospectively evaluated nine consecutive patients treated with low‐dose (1.9 mg/kg) B‐MAF.ResultsThe median age was 70 years. Most patients were penta‐refractory. Ocular toxicity was observed in 77.7%. Adverse events resulting in treatment delays were recorded in 9 out of 124 cycles being given. Overall response rate was 66% (6/9), and all responding patients achieved very good partial response or better. Within a median follow‐up of 12 (range 0.5–13.8) months, median progression‐free survival and overall survival were 14 (CI95% 6–22) and 20 (95%CI 0–41) months, respectively.ConclusionLow‐dose B‐MAF regimen showed high‐efficacy and low‐toxicity profile.
Subject
Hematology,General Medicine